BIO-TECHNE Corp 8-K

What Happened

• Bio‑Techne Corporation announced on June 25, 2026 that it entered into an Agreement and Plan of Merger with Merck KGaA, Darmstadt, Germany and Merck’s wholly owned subsidiary EMD Holdings NewCo, Inc. Under the agreement Merck’s subsidiary will merge into Bio‑Techne and Bio‑Techne will become a wholly owned subsidiary of Merck upon closing.
• The Board has approved the Merger Agreement and recommended that shareholders vote to approve the transaction. At the Effective Time each outstanding share of Bio‑Techne common stock (other than certain excluded or restricted shares) will be converted into the right to receive $73.00 in cash, subject to tax withholding.
• The agreement also sets out the cash treatment for employee equity: vested options paid in cash for the intrinsic value (number of shares × (73.00 − exercise price)); unvested options, RSUs and PSUs converted to fixed cash awards (performance awards deemed at target or maximum as specified); the Company will terminate its equity incentive plan and employee stock purchase plan prior to the Effective Time.

Key Details

• Merger consideration: $73.00 cash per share; Merger Agreement signed June 25, 2026; 8‑K filed June 26, 2026.
• Closing conditions: Company shareholder approval (majority of voting power), Hart‑Scott‑Rodino waiting period expiration and other antitrust/investment screening approvals, customary reps/warranties and covenants.
• Timing: Outside Date is March 25, 2027 (automatically extendable twice by three months — to June 25, 2027 and September 25, 2027 — if only antitrust/investment approvals remain outstanding).
• Termination fees and executive retention: Company Termination Fee = $230,455,000; Parent Termination Fee = $576,140,000 (subject to conditions). The Compensation Committee approved cash retention bonuses for named executives (effective upon the Merger Agreement): Kim Kelderman $2,120,976; Jim Hippel $1,541,510; William Geist $1,161,014; Shane Bohnen $971,097; Steve Crouse $910,263. Payments subject to continued employment or qualifying termination and a release; limited excise‑tax gross‑up provisions apply in specified circumstances.

Why It Matters

• For shareholders: If the deal closes as planned, holders of record will receive $73.00 per share in cash and Bio‑Techne will be taken private as a Merck subsidiary — subject to shareholder vote and regulatory approvals. The cash price and the Board’s recommendation make the transaction the central near‑term event for stockholders.
• For employees and executives: Equity awards and the stock purchase plan will be cashed out or terminated, and senior executives received significant retention bonuses to support continuity through closing.
• For timeline and risk: Completion depends on antitrust and other approvals and customary closing conditions; the Outside Date and sizable termination fees show both sides’ commitment but also the deal’s regulatory and timing uncertainty.